These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31708378)

  • 1. FGF23-klotho axis as predictive factors of fractures in type 2 diabetics with early chronic kidney disease.
    Ribeiro AL; Mendes F; Carias E; Rato F; Santos N; Neves PL; Silva AP
    J Diabetes Complications; 2020 Jan; 34(1):107476. PubMed ID: 31708378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Klotho levels: association with insulin resistance and albumin-to-creatinine ratio in type 2 diabetic patients.
    Silva AP; Mendes F; Pereira L; Fragoso A; Gonçalves RB; Santos N; Rato F; Neves PL
    Int Urol Nephrol; 2017 Oct; 49(10):1809-1814. PubMed ID: 28677090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
    Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria.
    Inci A; Sari F; Coban M; Olmaz R; Dolu S; Sarıkaya M; Yılmaz N
    J Investig Med; 2016 Aug; 64(6):1128-33. PubMed ID: 27323770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
    Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Levels of Soluble Klotho and Fibroblast Growth Factor 23 in Diabetic Patients and Its Association with Early Nephropathy.
    Farías-Basulto A; Martínez-Ramírez HR; Gómez-García EF; Cueto-Manzano AM; Cortés-Sanabria L; Hernández-Ramos LE; Ramírez-López G; Mendoza-Carrera F
    Arch Med Res; 2018 Oct; 49(7):451-455. PubMed ID: 30718148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased plasma α-Klotho predict progression of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Lee EY; Lee SM; Chung CH; Kwak IS; Lee EK; Kim YK
    J Diabetes Complications; 2016 Jul; 30(5):887-92. PubMed ID: 27037042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered serum levels of FGF-23 and magnesium are independent risk factors for an increased albumin-to-creatinine ratio in type 2 diabetics with chronic kidney disease.
    Silva AP; Mendes F; Fragoso A; Jeronimo T; Pimentel A; Gundlach K; Büchel J; Santos N; Neves PL
    J Diabetes Complications; 2016 Mar; 30(2):275-80. PubMed ID: 26750742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
    Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease].
    Lacroix JS; Urena-Torres P
    Nephrol Ther; 2020 Mar; 16(2):83-92. PubMed ID: 31843356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
    Desbiens LC; Sidibé A; Ung RV; Fortier C; Munger M; Wang YP; Bisson SK; Marquis K; Agharazii M; Mac-Way F
    Osteoporos Int; 2018 Oct; 29(10):2345-2353. PubMed ID: 29959497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
    Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
    Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture.
    Hughes-Austin JM; Katz R; Semba RD; Kritchevsky SB; Bauer DC; Sarnak MJ; Ginsberg C; Shlipak MG; Lima F; Malluche HH; Ix JH
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2903-11. PubMed ID: 32474604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.